[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380765-105":59,"doc-detail-380765-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liquid-biopsy-in-detecting-early-non-small-cell-lung-cancer","Liquid biopsy in detecting early non-small cell lung cancer","","Lung cancer screening programs using low-dose computed tomography (CT) have reduced cancer-related deaths, prompting research into cell-free DNA testing to detect pre-diagnostic mutations years before clinical diagnosis and to stratify high-risk individuals. Although such strategies have revealed precursors in other diseases, occult preneoplasia in non-small-cell lung cancer (NSCLC) remains insufficiently characterized. The TRACERx consortium studies detection and progression of NSCLC to monitor disease, predict treatment response, and uncover driver mutations and fusion genes, while calling for more mechanistic clinical focus.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsy-in-detecting-early-non-small-cell-lung-cancer/380765/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsy-in-detecting-early-non-small-cell-lung-cancer/380765.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does liquid biopsy aim to improve early non-small cell lung cancer detection?","Question",{"text":112,"@type":113},"Liquid biopsy evaluates cell-free DNA and other circulating molecular signals to identify pre-diagnostic mutations and related precursors before clinical diagnosis, supporting risk stratification.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does the TRACERx consortium play in NSCLC research?",{"text":117,"@type":113},"TRACERx conducts extensive studies to characterize how NSCLC is detected and progresses, using liquid biopsy to monitor disease, predict treatment response, and identify actionable driver mutations and fusion genes.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is additional investigation needed for NSCLC occult preneoplasia?",{"text":121,"@type":113},"While similar approaches have identified precursors in other conditions, the presence and characterization of occult lung preneoplasia in NSCLC still require further research.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380765,1790387054,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Journal of Liquid Biopsy 1 (2023) 100001  \nContents lists available at ScienceDirect  \nThe Journal of Liquid Biopsy  \njournal [homepage:](homepage: www.sciencedirect.com/journal/the-journal-of-liquid-biopsy)[ www.sciencedirect.com/journal/the-journal-of-liquid-biopsy](homepage: www.sciencedirect.com/journal/the-journal-of-liquid-biopsy)  \nLiquid biopsy in detecting early non-small cell lung cancer  \nRafael Rosell a, b, c, *, Mariacarmela Santarpia d, Carlos Pedraz-Valdunciel e, Giuliana Ciappinad, Andrs Aguilar c, Ana Gimnez-Capitn f, Masaoki Ito g, Maria Gonzlez-Cao c,  \nMiguel Angel Molina-Vila f  \na Germans Trias i Pujol Health Sciences Institute and Hospital (IGTP), Badalona, Spain  \nb Catalan Institute of Oncology, Badalona, Spain  \nc Instituto Oncolgico Dr Rosell, Dexeus University Hospital, Barcelona, Spain  \nd Department of Human Pathology “G. Barresi”, Medical Oncology Unit, University of Messina, Messina, Italy  \ne Invitrocue, Barcelona, Spain  \nf Pangaea Oncology, Dexeus University Hospital, Barcelona, Spain  \ng Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan  \nA R T I C L E I N F O  \nKeywords: KRAS Liquid biopsy LKB1  \nBiomarkers,  \nCircRNAs and NSCLC  \nA B S T R A C T  \nLung cancer screening programs, particularly in the UK, have shown a decrease in lung cancer-related deaths among individuals who underwent low-dose computed tomography (CT) screening. Researchers are now focusing on evaluating cell-free DNA through various methods to determine if pre-diagnostic mutations can be detected years before clinical diagnosis. This could help identify individuals at high risk of developing lung cancer. However, while this approach has successfully identified precursors of follicular lymphoma, the presence of occult lung preneoplasia in non-small-cell lung cancer still requires further investigation.  \nThe TRACERx consortium is conducting extensive research to comprehensively assess the detection and progression of non-small cell lung cancers (NSCLC). Liquid biopsy is being used in advanced stages of the disease to monitor disease progression, predict treatment response, and identify targetable driver oncogenic mutations and fusion genes. Intense research is also underway to identify numerous diagnostic gene signatures with high accuracy for early-stage lung cancer. However, a more focused clinical approach is needed, with a mechanistic focus on the key pathways of cancer development.  \nLoss of liver kinase B1 (LKB1) function and deactivation due to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of tobacco-specific carcinogens, could potentially be traced and contribute to the development of new biomarkers. This testing could complement machine-learning approaches. The discovery of epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in healthy lung tissues by TRACERx investigators may also lead to the development of novel diagnostic tools. Tumor protein 53 (TP53) loss should also be considered as a marker that could contribute to malignant transformation. Intercepting aggressive non-small-cell lung cancer is a pressing priority.  \nIn this review, we discuss our experience and explore other research on exosomes and plasma circular RNA as potential biomarkers. Circular RNAs, formed through non-sequential back-splicing of pre-mRNA transcripts, playa role in epithelial-mesenchymal transition, with many of them regulated by the RNA-binding protein Quaking. Platelet RNA has shown promise in detecting early and late-stage cancer. The extensive exploration of liquid biopsy aims to provide affordable methods for tracing circulating precursors of non-small-cell lung cancer, highlighting the importance of its mission.  \nIntroduction  \nLung cancer is the main cause of all cancer mortality, primarily due to cigarette smoking. The risk of developing lung cancer is associated with  \nvari","cbCaio3MAVVw3g6l","https://ap.wps.com/l/cbCaio3MAVVw3g6l","pdf",1024580,"English","# Introduction\n## Lung cancer risk and smoking-related mutation accumulation\n## Low-dose CT screening and mortality evidence\n## Clinical trial landmarks (ELCAP, NSLT, NELSON, LUSI)","[{\"question\":\"How does liquid biopsy aim to improve early non-small cell lung cancer detection?\",\"answer\":\"Liquid biopsy evaluates cell-free DNA and other circulating molecular signals to identify pre-diagnostic mutations and related precursors before clinical diagnosis, supporting risk stratification.\"},{\"question\":\"What role does the TRACERx consortium play in NSCLC research?\",\"answer\":\"TRACERx conducts extensive studies to characterize how NSCLC is detected and progresses, using liquid biopsy to monitor disease, predict treatment response, and identify actionable driver mutations and fusion genes.\"},{\"question\":\"Why is additional investigation needed for NSCLC occult preneoplasia?\",\"answer\":\"While similar approaches have identified precursors in other conditions, the presence and characterization of occult lung preneoplasia in NSCLC still require further research.\"}]","Liquid biopsy in detecting early non-small cell lung cancer | PDF",1790241932,23]